Ayala Pharmaceuticals Public
Ayala Pharmaceuticals is a clinical-stage biopharmaceutical company that focuses on developing and commercializing small molecule therapeutics for rare and aggressive cancers. Their main goal is to provide targeted therapies to underserved patient populations by identifying and addressing tumorigenic drivers of cancer. The company has two product candidates, AL101 and AL02, which target the aberrant activation of the Notch pathway to treat various tumors. In 2024, Ayala Pharmaceuticals was acquired by Immunome, Inc. for their AL102 and AL101 products.
Technology:
Biotechnology, Pharmaceutical
Headquarters:
Rehovot, Israel
Funding Status:
Early Stage Venture
Investment Stage:
N/A
Founded Date:
2017
Number Of Exists:
N/A
Employee Number:
10-50
Industry:
PharmTech
Investor Type:
N/A